What Immucor does

Immucor Inc., founded in 1982 and headquartered in Norcross, Georgia, is a specialized diagnostics company focused on transfusion medicine, transplantation, and coagulation testing. Its core franchise spans automated immunohematology instruments (the Echo Lumena® and NEO Iris® analyzers), a broad reagent menu built on the patented Capture® solid phase technology, and a transplant diagnostics portfolio anchored by MIA FORA™ NGS HLA typing kits, LIFECODES® antibody detection assays, and supporting software including ImmuLINK® data management and MATCH IT!® DNA interpretation. The product surface also extends into molecular post-transplant monitoring via the Immucor DX sub-brand (including the KSort platform), platelet antibody testing, infectious disease screening (Capture-CMV), and coagulation diagnostics for HIT (PF4 assays) and TTP (ATS-13®).

Immucor operates as a B2B enterprise diagnostics company with a global direct sales model and regional offices in 12+ countries across North America, Europe, and Asia-Pacific. Customers include hospital blood banks, transplant programs, clinical and reference laboratories, blood donor centers, and coagulation testing labs, with named references spanning academic medical centers, community hospitals, organ procurement organizations, and government blood services. The company's value proposition rests on proprietary wet-lab chemistry, instrument-reagent lock-in, validated laboratory workflows, and a sales force composed of former transplant technologists.

In March 2023, Immucor was acquired by Spain-based Werfen S.A. for approximately $2 billion and now operates as a wholly-owned subsidiary under Werfen's transfusion and transplant division, marketing its products through the transfusionandtransplant.werfen.com channel while retaining the Immucor brand and product sub-brands. Werfen followed the acquisition with the 2024 purchase of Budapest-based Omixon to expand the HLA typing software portfolio, and Immucor continues to release new products including the NanoTYPE™ HLA-11 Plus HLA typing kit, which secured CE-IVD marking in November 2025. Revenue is not publicly disclosed; the company is no longer an independent public entity.

Name

Immucor

Legal name

Immucor Inc.

Website

https://immucor.com

Company type

Private

Founded year

1982

Operating status

Acquired

Headcount range

1,001–5,000 employees

Short description

Immucor is a US-based specialized diagnostics company that develops instruments, reagents, and software for transfusion, transplantation, and coagulation testing. It sells Capture® solid-phase assays, NEO Iris® and Echo Lumena® analyzers, and HLA typing kits to hospitals, transplant centers, reference labs, and donor centers globally, operating as a Werfen S.A. subsidiary since 2023.

Ownership category

akta.pro rank

Product category

Transfusion and Transplantation Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

akta.pro secondary industries

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Hematology & Coagulation Diagnostics (HLAHAAAB), Immunoassay Diagnostics (ELISA, chemiluminescence, serology) (HLAAALAB), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG)

Keywords

• Transfusion diagnostics
• Transplant diagnostics
• Immunohematology reagents
• HLA typing kits
• Blood bank automation

Headquarters

HQ city

Norcross

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Transfusion Diagnostics Products: Products for blood group typing, antibody screening, and pre-transfusion testing including reagents, instruments, and consumables
2. Transplant Diagnostics Products: HLA typing kits, antibody detection products, and software for organ and bone marrow transplant matching and monitoring
3. Coagulation Diagnostics: Products for diagnosis of Heparin-Induced Thrombocytopenia (HIT) and Thrombotic Thrombocytopenic Purpura (TTP)

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Immucor manufactures and sells a comprehensive portfolio of specialized diagnostic products for transfusion medicine, transplantation, and coagulation testing. Offerings include automated blood bank instruments (Echo Lumena, NEO Iris), serology and molecular reagents, HLA typing kits, antibody detection assays, and data management software, all powered by the patented Capture solid phase technology, sold to hospital blood banks, transplant programs, reference laboratories, and donor centers.

Product overview

Immucor, now part of Werfen, offers a comprehensive portfolio of specialized diagnostic products for transfusion medicine, transplantation diagnostics, and coagulation testing. The product portfolio is organized into three main segments: Transfusion (automation instruments like Echo Lumena® and NEO Iris®, serology and molecular reagents, platelet testing, and HLA donor screening), Transplant (HLA typing kits including MIA FORA™ NGS and LIFECODES® products, antibody detection and identification assays including single antigen and complement detection, software solutions like MATCH IT!® and ImmuLINK®), and Coagulation (PF4 assays for HIT diagnosis and ATS-13® for TTP diagnosis). The portfolio is powered by proprietary technologies including Capture® solid phase technology used across instruments and reagents for antibody detection. The products work together to enable donor-recipient compatibility testing, pre-transfusion testing, and post-transplant rejection monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• Immucor DX: Transfusion molecular testing and post-transplant monitoring platform including KSort for post transplant monitoring
• Capture
• LIFECODES
• NEO Iris
• Echo Lumena
• ImmuLINK
• NanoTYPE

Products and services

• Echo Lumena Automated instrument for transfusion testing that provides fast turnaround times, high throughput, and instant access to results, using Capture solid phase technology to support immunohematology testing for hospital blood banks.
• NEO Iris Automated blood bank instrument offering high efficiency and reliability for type and screen samples, enabling laboratories to automate all type and screen workflows using Capture solid phase technology.
• ImmuLINK Data Management Software for managing transfusion testing results and laboratory workflow, including a panel ID algorithm that supports antibody identification decisions for blood bank operations.
• Capture Workstation Automation workstation that operationalizes the Capture solid phase technology platform for blood bank testing workflows.
• Molecular RBC Typing Molecular-based red blood cell antigen typing test that delivers precise antigen profiling beyond serology for hospitals and donor centers.
• Gemini HLA donor screening assay designed to deliver reliable and cost-effective screening of blood donors for transfusion safety in donor centers and blood banks.
• Automated Capture-R Ready-Screen Automated antibody screening assay using Capture-R solid phase technology for routine and high-volume blood bank screening.
• Automated Capture-R Ready-ID Automated antibody identification assay using Capture-R solid phase technology for resolving antibody specificities in blood bank laboratories.
• Automated Titrations Automated titration assay for ABO compatibility assessment in solid organ transplant programs and reference laboratories.
• MIA FORA NGS MFlex HLA Typing Kits Next-generation sequencing HLA typing kits in multiple configurations, delivered with user-friendly NGS analysis software for transplant laboratories.
• LIFECODES HLA SSO Typing Kits Sequence-specific oligonucleotide (SSO) HLA typing kits for routine HLA classification in transplant laboratories.
• MATCH IT! DNA Software DNA analysis software that interprets HLA typing data for transplant laboratories to support donor-recipient matching decisions.
• MIA FORA NGS Software Companion software for the MIA FORA NGS HLA typing kits, providing data analysis capabilities for transplant laboratories.
• LIFECODES LifeScreen Assays HLA antibody screening assays used to evaluate transplant recipients as part of the LIFECODES antibody detection portfolio.
• LIFECODES Class I and Class II ID HLA antibody identification assays that distinguish Class I and Class II antibodies for donor-recipient matching.
• LIFECODES Single Antigen Assays (LSA) Single antigen bead assays for precise determination of HLA antibody specificities in highly sensitized transplant candidates.
• LIFECODES Donor Specific Antibody Assay Donor-specific antibody detection assay for monitoring transplant recipients for rejection risk after transplantation.
• MATCH IT! Antibody Analysis Software Antibody analysis software for transplant immunology data interpretation within the LIFECODES portfolio.
• PF4 Enhanced and PF4 IgG Assay Immunoassays for the diagnosis of Heparin-Induced Thrombocytopenia (HIT) by detecting PF4-heparin antibodies in patient samples.
• ATS-13 Activity Assay Activity assay supporting the diagnosis of Thrombotic Thrombocytopenic Purpura (TTP) by measuring ADAMTS13 activity in patient samples.
• LIFECODES LSA-MIC Assay MICA (MHC class I polypeptide-related sequence A) antibody detection assay that complements the LIFECODES single antigen portfolio for transplant matching.
• LIFECODES C3d Assay Complement C3d detection assay used to identify complement-binding HLA antibodies relevant to transplant risk assessment.
• LIFECODES Non-HLA Antibody Assay Assay for detecting non-HLA antibodies relevant to transplant outcomes where standard HLA antibodies do not fully explain clinical risk.
• NanoTYPE HLA-11 Plus Next-generation sequencing HLA typing kit providing true full-gene coverage across all 11 classical HLA genes for research use in transplant laboratories.

Quantifiable outcome

• Automation enabled handling all type & screen samples on NEO instrument
• +2 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• OmixoncoreStrategic or Co-development PartnerOmixon, a privately held company based in Budapest, Hungary, was acquired by Werfen to expand the specialized diagnostics portfolio. This acquisition complements the existing Immucor offerings in transfusion and transplant diagnostics, combining expertise in HLA typing technologies.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bio-Rad Laboratories: Bio-Rad is a direct competitor in transfusion medicine with its IH-1000 automated immunohematology analyzer and serology/molecular blood typing reagents, serving the same hospital blood bank and reference laboratory customers as Immucor.
• Grifols: Grifols competes with Immucor through its Progenika blood genotyping and immunohematology diagnostics portfolio, targeting blood banks and donor centers with molecular and serology products for transfusion medicine.
• Quotient: Quotient is a transfusion diagnostics specialist offering the MosaiQ platform for blood grouping and serological disease screening, directly competing with Immucor's transfusion automation portfolio.
• Ortho Clinical Diagnostics: Ortho Clinical Diagnostics is a direct competitor with its Vision series and ORTHO VISION Max analyzers for immunohematology, overlapping with Immucor's NEO Iris and Echo Lumena in hospital blood banks.
• GenDx: GenDx is an NGS-based HLA typing specialist serving transplant laboratories, directly competing with Immucor's LIFECODES and MIA FORA NGS HLA typing kits and software.

Emerging players

• CareDx: CareDx focuses on transplant diagnostics including donor-derived cell-free DNA and HLA typing, intersecting with Immucor's transplant franchise in post-transplant monitoring and donor-recipient matching.

Broad incumbents

• Thermo Fisher Scientific: Thermo Fisher is a broad IVD and life sciences incumbent with transplant and immunogenetics products (e.g., One Lambda HLA typing) overlapping with Immucor's transplant diagnostics business.
• Danaher (Beckman Coulter): Danaher, through Beckman Coulter, offers a broad diagnostics portfolio including hematology and clinical chemistry, and competes in adjacent IVD categories that overlap with Immucor's hospital and reference lab customers.
• Abbott: Abbott is a diversified diagnostics leader with immunoassay and blood screening products (including post-Genzyme transplant testing) that overlap with Immucor's transplant and blood bank segments.

Others

• Werfen (parent): Werfen is the Spanish diagnostics parent that acquired Immucor for ~$2B in March 2023 and subsequently acquired Omixon, including them in its transfusion and transplant diagnostics portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/immucor
• YouTubeyoutube.com/channel/UCiHYsw2ICh3KWkGYziy1nhw
• Facebookfacebook.com/immucor
• LinkedInlinkedin.com/company/immucor-official
• Instagraminstagram.com/immucor_official

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immucor